中国实用妇科与产科杂志

中国实用妇科与产科杂志

• 专题笔谈 • 上一篇    下一篇

妇科恶性肿瘤术后性激素治疗及风险

  

  1. 1.中国医学科学院 北京协和医院妇产科，北京100730；2.苏州市立医院，江苏 苏州 215008
  • 出版日期:2019-06-02 发布日期:2019-06-03
  • 通讯作者: 陈蓉
  • 基金资助:

    国家自然科学基金（81871141）

Hormone therapy and its risk after gynecological malignancy operation.

  1. Department of Obstetrics and Gynecology，Peking Union Medical College Hospital，Peking Union Medical College & Chinese Academy of Medical Science，Beijing 100730，China
  • Online:2019-06-02 Published:2019-06-03

摘要：

随着治疗水平提升，妇科恶性肿瘤患者生存期不断延长，因而改善妇科恶性肿瘤生存者的生存质量成为医生们面临的新挑战。妇科恶性肿瘤患者可能自身正处于围绝经期，也可能是由于肿瘤治疗导致人工绝经，其更年期症状可能较正常年龄自然绝经女性更明显。对于妇科恶性肿瘤术后患者是否可以给予性激素治疗，目前仍有一定争议。临床医生需针对不同的原发病，在患者知情同意的基础上，审慎个体化用药。

关键词: 妇科恶性肿瘤, 子宫颈癌, 子宫内膜癌, 卵巢癌, 性激素治疗

Abstract:

With the improvement of therapy，the survival time of patients with gynecological malignant tumor is prolonged，so improving their quality of life has become a new challenge for doctors.These patients may be in perimenopause themselves，or be in artificial menopause due to tumor treatment，and their climacteric symptoms are more obvious than those in natural menopause.Whether hormone therapy could be used to relieve the climacteric symptoms in these patients is still controversial at present.Clinicians should give individualized hormone therapy cautiously on the basis of patients' informed consent.

Key words: gynecological malignancy, cervical cancer, endometrial carcer, ovarian cancer, hormone therapy

中图分类号: